8-K Announcements
6Material company update
Mar 3, 2026·SEC
Material company update
Feb 20, 2026·SEC
Material company update
Jan 26, 2026·SEC
Amicus Therapeutics, Inc.(FOLD)Earnings, Financials & Key Ratios
FOLD•NASDAQ
$14.49
$4.47B mkt cap·Price updated May 6, 2026
AboutAmicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.Show more
- Revenue$528M+32.3%
- EBITDA$33M+148.2%
- Net Income-$56M+63.0%
- EPS (Diluted)-0.18+64.7%
- Gross Margin89.98%-0.7%
- EBITDA Margin6.33%+136.4%
- Operating Margin4.71%+124.4%
- Net Margin-10.62%+72.0%
- ROE-31.68%+70.4%
- ROIC4.77%+132.3%
- Debt/Equity2.29-17.7%
- Interest Coverage0.50+132.6%
FOLD Key Insights
Amicus Therapeutics, Inc. (FOLD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 84 (top 16%)
- ✓Strong 5Y sales CAGR of 23.7%
- ✓Trading near 52-week high
✗Weaknesses
- ✗High debt to equity ratio of 2.3x
- ✗Negative free cash flow
- ✗Expensive at 22.7x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
FOLD Price & Volume
Amicus Therapeutics, Inc. (FOLD) stock price & volume — 10-year historical chart
Loading chart...
FOLD Growth Metrics
Amicus Therapeutics, Inc. (FOLD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years83.45%
5 Years23.72%
3 Years20.03%
TTM21.28%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM86.57%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM87%
Return on Capital
10 Years-30.17%
5 Years-20.23%
3 Years-13.5%
Last Year3.99%
FOLD Recent Earnings
Amicus Therapeutics, Inc. (FOLD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 6/12 qtrs (50%)
Q1 2026Latest
Feb 20, 2026EPS
$0.01
Est $0.07
-86.0%
Revenue
$185M
Est $181M
+2.6%
Q4 2025
Nov 4, 2025EPS
$0.17
Est $0.12
+41.7%
Revenue
$169M
Est $185M
-8.6%
Q3 2025
Jul 31, 2025EPS
$0.01
Est $0.02
-50.0%
Revenue
$155M
Est $165M
-6.4%
Q2 2025
May 1, 2025EPS
$0.03
Est $0.08
-62.5%
Revenue
$125M
Est $147M
-15.1%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 20, 2026 | $0.01vs $0.07-86.0% | $185Mvs $181M+2.6% |
| Q4 2025 | Nov 4, 2025 | $0.17vs $0.12+41.7% | $169Mvs $185M-8.6% |
| Q3 2025 | Jul 31, 2025 | $0.01vs $0.02-50.0% | $155Mvs $165M-6.4% |
| Q2 2025 | May 1, 2025 | $0.03vs $0.08-62.5% | $125Mvs $147M-15.1% |
Based on last 12 quarters of dataView full earnings history →
FOLD Peer Comparison
Amicus Therapeutics, Inc. (FOLD) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RARE | 2.46B | 25.01 | -4.29 | 20.13% | -85.54% | -9.11% | ||
 SRPT | 2.28B | 21.79 | 9.31 | 52.97% | -11.25% | -20.57% | 0.88 | |
 BMRN | 10.24B | 53.24 | 29.58 | 12.87% | 8.29% | 4.41% | 7.08% | 0.11 |
 IONS | 12.44B | 75.25 | -31.62 | 33.87% | -30.87% | -58.57% | 5.35 | |
 KRYS | 8.38B | 284.57 | 41.60 | 33.94% | 53.92% | 19.25% | 2.26% | 0.01 |
 ACAD | 3.78B | 22.35 | 16.43 | 31.85% | 24.94% | 28.47% | 4.16% | 0.07 |
 PTCT | 5.39B | 65.04 | 8.36 | 114.51% | 39.44% | 13.02% | ||
 LGND | 4.57B | 232.30 | -1055.91 | 27.28% | 19.34% | 5.11% | 1.7% | 0.01 |
Compare FOLD vs Peers
Amicus Therapeutics, Inc. (FOLD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
FOLD Income Statement
Amicus Therapeutics, Inc. (FOLD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 4.96M | 36.93M | 91.25M | 182.24M | 260.89M | 305.51M | 329.23M | 399.36M | 528.29M | 598.7M |
| Revenue Growth % | - | 644.86% | 147.08% | 99.72% | 43.16% | 17.11% | 7.76% | 21.3% | 32.29% | 21.28% |
| Cost of Goods Sold | 833K | 6.24M | 14.4M | 21.96M | 31.04M | 34.47M | 38.6M | 37.33M | 52.94M | 63.09M |
| COGS % of Revenue | 16.8% | 16.89% | 15.79% | 12.05% | 11.9% | 11.28% | 11.72% | 9.35% | 10.02% | - |
| Gross Profit | 4.13M▲ 0% | 30.69M▲ 644.1% | 76.84M▲ 150.3% | 160.27M▲ 108.6% | 229.84M▲ 43.4% | 271.05M▲ 17.9% | 290.63M▲ 7.2% | 362.03M▲ 24.6% | 475.35M▲ 31.3% | 535.61M▲ 0% |
| Gross Margin % | 83.2% | 83.11% | 84.21% | 87.95% | 88.1% | 88.72% | 88.28% | 90.65% | 89.98% | 89.46% |
| Gross Profit Growth % | 325.04% | 644.1% | 150.35% | 108.58% | 43.41% | 17.93% | 7.23% | 24.57% | 31.3% | - |
| Operating Expenses | 179.19M | 241.57M | 402.32M | 464.31M | 476.84M | 477.48M | 502.75M | 439.24M | 450.48M | 502.8M |
| OpEx % of Revenue | 3614.08% | 654.14% | 440.92% | 254.78% | 182.78% | 156.29% | 152.7% | 109.99% | 85.27% | - |
| Selling, General & Admin | 71.15M | 88.67M | 127.2M | 169.86M | 156.41M | 192.71M | 213.04M | 275.27M | 323.38M | 353.07M |
| SG&A % of Revenue | 1435.07% | 240.11% | 139.4% | 93.21% | 59.95% | 63.08% | 64.71% | 68.93% | 61.21% | - |
| Research & Development | 104.79M | 149.31M | 270.9M | 286.38M | 308.44M | 272.05M | 276.68M | 152.38M | 109.36M | 142.29M |
| R&D % of Revenue | 2113.61% | 404.31% | 296.9% | 157.15% | 118.23% | 89.05% | 84.04% | 38.16% | 20.7% | - |
| Other Operating Expenses | -4.79M | 6.01M | -5.63M | 8.07M | 11.99M | 12.72M | 13.04M | 11.59M | 17.73M | 3M |
| Operating Income | -181.89M▲ 0% | -441.99M▼ 143.0% | -328.78M▲ 25.6% | -304.04M▲ 7.5% | -247M▲ 18.8% | -206.43M▲ 16.4% | -212.12M▼ 2.8% | -77.21M▲ 63.6% | 24.88M▲ 132.2% | 32.81M▲ 0% |
| Operating Margin % | -3668.62% | -1196.82% | -360.32% | -166.84% | -94.68% | -67.57% | -64.43% | -19.33% | 4.71% | 5.48% |
| Operating Income Growth % | -39.45% | -143% | 25.61% | 7.52% | 18.76% | 16.42% | -2.75% | 63.6% | 132.22% | - |
| EBITDA | -178.65M | -438.39M | -324.56M | -299.26M | -238.15M | -200.22M | -206.78M | -69.34M | 33.42M | 40.42M |
| EBITDA Margin % | -3603.23% | -1187.09% | -355.7% | -164.22% | -91.29% | -65.54% | -62.81% | -17.36% | 6.33% | 6.75% |
| EBITDA Growth % | -38.91% | -145.39% | 25.97% | 7.79% | 20.42% | 15.93% | -3.27% | 66.47% | 148.2% | 190.76% |
| D&A (Non-Cash Add-back) | 3.24M | 3.59M | 4.22M | 4.78M | 8.85M | 6.21M | 5.34M | 7.87M | 8.55M | 7.6M |
| EBIT | -198.38M | -431.88M | -326.69M | -337.04M | -251.83M | -209.08M | -204.92M | -99.95M | 20.84M | 51.67M |
| Net Interest Income | -3.8M | -13.14M | -11.94M | -8.62M | -19.2M | -31.96M | -34.09M | -43.07M | -44.19M | -42.79M |
| Interest Income | 1.6M | 4.1M | 10.46M | 10.25M | 3.23M | 509K | 3.02M | 7.08M | 5.41M | 3.9M |
| Interest Expense | 5.4M | 17.24M | 22.4M | 18.87M | 22.43M | 32.47M | 37.12M | 50.15M | 49.6M | 46.69M |
| Other Income/Expense | -21.89M | -7.14M | -23.61M | -51.87M | -27.26M | -35.12M | -29.92M | -72.89M | -53.63M | -27.83M |
| Pretax Income | -203.78M▲ 0% | -449.12M▼ 120.4% | -349.09M▲ 22.3% | -355.91M▼ 2.0% | -274.25M▲ 22.9% | -241.55M▲ 11.9% | -242.04M▼ 0.2% | -150.1M▲ 38.0% | -28.76M▲ 80.8% | 4.98M▲ 0% |
| Pretax Margin % | -4110.15% | -1216.14% | -382.58% | -195.3% | -105.12% | -79.06% | -73.52% | -37.59% | -5.44% | 0.83% |
| Income Tax | -3.74M | -165.12M | -94K | 478K | 2.6M | 8.91M | -5.47M | 1.48M | 27.35M | 19.04M |
| Effective Tax Rate % | 1.83% | 36.76% | 0.03% | -0.13% | -0.95% | -3.69% | 2.26% | -0.99% | -95.11% | 382.24% |
| Net Income | -200.04M▲ 0% | -284M▼ 42.0% | -349M▼ 22.9% | -356.39M▼ 2.1% | -276.85M▲ 22.3% | -250.46M▲ 9.5% | -236.57M▲ 5.5% | -151.58M▲ 35.9% | -56.11M▲ 63.0% | -14.06M▲ 0% |
| Net Margin % | -4034.73% | -769.03% | -382.48% | -195.56% | -106.12% | -81.98% | -71.85% | -37.96% | -10.62% | -2.35% |
| Net Income Growth % | -51.41% | -41.97% | -22.88% | -2.12% | 22.32% | 9.53% | 5.55% | 35.92% | 62.99% | 86.57% |
| Net Income (Continuing) | -200.04M | -284M | -349M | -356.39M | -276.85M | -250.46M | -236.57M | -151.58M | -56.11M | -14.06M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.49▲ 0% | -1.85▼ 24.2% | -1.88▼ 1.6% | -1.48▲ 21.3% | -1.07▲ 27.7% | -0.92▲ 14.0% | -0.82▲ 10.9% | -0.51▲ 37.8% | -0.18▲ 64.7% | -0.05▲ 0% |
| EPS Growth % | -24.17% | -24.16% | -1.62% | 21.28% | 27.7% | 14.02% | 10.87% | 37.8% | 64.71% | 87% |
| EPS (Basic) | -1.49 | -1.85 | -1.88 | -1.48 | -1.07 | -0.92 | -0.82 | -0.51 | -0.18 | - |
| Diluted Shares Outstanding | 134.4M | 153.36M | 185.79M | 240.42M | 258.87M | 271.42M | 289.06M | 295.16M | 304.38M | 310.43M |
| Basic Shares Outstanding | 134.4M | 153.36M | 185.79M | 240.42M | 258.87M | 271.42M | 289.06M | 295.16M | 304.38M | 308.47M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
FOLD Balance Sheet
Amicus Therapeutics, Inc. (FOLD) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 340.06M | 391.96M | 551.1M | 520.07M | 579.47M | 596.83M | 423.82M | 483.06M | 504.74M | 594.07M |
| Cash & Short-Term Investments | 330.35M | 358.56M | 504.15M | 452.74M | 483.27M | 482.5M | 293.6M | 286.2M | 249.95M | 263.84M |
| Cash Only | 187.03M | 49.06M | 79.75M | 142.84M | 163.24M | 245.2M | 148.81M | 246.99M | 213.75M | 190.55M |
| Short-Term Investments | 143.32M | 309.5M | 424.4M | 309.9M | 320.03M | 237.3M | 144.78M | 39.21M | 36.19M | 73.29M |
| Accounts Receivable | 1.3M | 9.46M | 21.96M | 33.28M | 46.92M | 52.67M | 66.2M | 87.63M | 101.1M | 113.84M |
| Days Sales Outstanding | 96 | 93.54 | 87.85 | 66.66 | 65.65 | 62.93 | 73.39 | 80.09 | 69.85 | 62.35 |
| Inventory | 3.42M | 4.62M | 8.39M | 14.04M | 19.56M | 26.82M | 23.82M | 59.7M | 118.78M | 177.93M |
| Days Inventory Outstanding | 1.5K | 270.59 | 212.6 | 233.35 | 229.93 | 284.01 | 225.21 | 583.75 | 818.91 | 844.64 |
| Other Current Assets | 4.99M | 19.32M | 16.59M | 0 | 0 | 0 | 40.21M | 49.53M | 34.91M | 0 |
| Total Non-Current Assets | 696.78M | 235.06M | 238.85M | 330.13M | 307.05M | 308.31M | 300.35M | 294.82M | 280.3M | 274.75M |
| Property, Plant & Equipment | 9.82M | 9.06M | 11.38M | 81.02M | 67.16M | 63.08M | 60.31M | 57.98M | 51.66M | 49.31M |
| Fixed Asset Turnover | 0.51x | 4.08x | 8.02x | 2.25x | 3.88x | 4.84x | 5.46x | 6.89x | 10.23x | 11.83x |
| Goodwill | 197.8M | 197.8M | 197.8M | 197.8M | 197.8M | 197.8M | 197.8M | 197.8M | 197.8M | 197.8M |
| Intangible Assets | 486.7M | 23M | 23M | 23M | 23M | 23M | 23M | 20.49M | 17.2M | 14.74M |
| Long-Term Investments | -173.77M | -6.46M | -6.46M | 0 | 0 | 0 | 0 | 0 | 0 | 3.31M |
| Other Non-Current Assets | 2.47M | 5.2M | 6.68M | 28.32M | 19.09M | 24.43M | 19.24M | 18.55M | 13.64M | 50.59M |
| Total Assets | 1.04B▲ 0% | 627.02M▼ 39.5% | 789.95M▲ 26.0% | 850.21M▲ 7.6% | 886.52M▲ 4.3% | 905.14M▲ 2.1% | 724.17M▼ 20.0% | 777.88M▲ 7.4% | 785.03M▲ 0.9% | 868.81M▲ 0% |
| Asset Turnover | 0.00x | 0.06x | 0.12x | 0.21x | 0.29x | 0.34x | 0.45x | 0.51x | 0.67x | 0.73x |
| Asset Growth % | 14.14% | -39.53% | 25.98% | 7.63% | 4.27% | 2.1% | -19.99% | 7.42% | 0.92% | 29.59% |
| Total Current Liabilities | 110.96M | 70.04M | 86.13M | 128.81M | 129.68M | 145.97M | 139.02M | 167.69M | 148.7M | 198.93M |
| Accounts Payable | 12.9M | 7.87M | 6.61M | 21.72M | 17.06M | 21.51M | 15.41M | 15.12M | 12.95M | 19.1M |
| Days Payables Outstanding | 5.65K | 460.46 | 167.4 | 360.99 | 200.62 | 227.83 | 145.75 | 147.85 | 89.26 | 87.35 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 69.4M | 7.75M | 5.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 23.8M | 30.82M | 32.06M | 31.18M | 27.12M | 28.46M | 33.17M | 48.68M | 41.23M | 0 |
| Current Ratio | 3.06x | 5.60x | 6.40x | 4.04x | 4.47x | 4.09x | 3.05x | 2.88x | 3.39x | 3.39x |
| Quick Ratio | 3.03x | 5.53x | 6.30x | 3.93x | 4.32x | 3.90x | 2.88x | 2.52x | 2.60x | 2.60x |
| Cash Conversion Cycle | -4.06K | -96.34 | 133.06 | -60.99 | 94.96 | 119.11 | 152.85 | 515.99 | 799.5 | 819.64 |
| Total Non-Current Liabilities | 565.74M | 204.13M | 360.91M | 244.97M | 470.46M | 451.8M | 462.1M | 450.02M | 442.29M | 439.46M |
| Long-Term Debt | 154.46M | 164.17M | 321.74M | 149.5M | 389.25M | 389.36M | 391.99M | 387.86M | 390.11M | 391.99M |
| Capital Lease Obligations | 0 | 0 | 0 | 53.53M | 45.6M | 43.36M | 51.58M | 48.88M | 45.08M | 174.83M |
| Deferred Tax Liabilities | 173.77M | 6.46M | 6.46M | 5.05M | 4.9M | 4.93M | 4.94M | 0 | 0 | 0 |
| Other Non-Current Liabilities | 237.5M | 33.5M | 32.71M | 36.88M | 30.71M | 14.15M | 13.6M | 13.28M | 7.1M | 29.53M |
| Total Liabilities | 676.69M | 274.17M | 447.04M | 373.78M | 600.14M | 597.77M | 601.12M | 617.71M | 590.99M | 638.39M |
| Total Debt | 154.46M | 164.47M | 321.74M | 210.22M | 441.73M | 440.13M | 452.12M | 445.06M | 443.64M | 442.82M |
| Net Debt | -32.56M | 115.41M | 241.99M | 67.39M | 278.49M | 194.93M | 303.31M | 198.06M | 229.89M | 252.27M |
| Debt / Equity | 0.43x | 0.47x | 0.94x | 0.44x | 1.54x | 1.43x | 3.67x | 2.78x | 2.29x | 2.29x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | 13.27x | 10.96x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | 6.88x | 6.88x |
| Interest Coverage | -33.70x | -25.64x | -14.68x | -16.11x | -11.01x | -6.36x | -5.71x | -1.54x | 0.50x | 1.11x |
| Total Equity | 360.15M▲ 0% | 352.85M▼ 2.0% | 342.91M▼ 2.8% | 476.43M▲ 38.9% | 286.38M▼ 39.9% | 307.37M▲ 7.3% | 123.05M▼ 60.0% | 160.17M▲ 30.2% | 194.04M▲ 21.1% | 230.42M▲ 0% |
| Equity Growth % | 3.54% | -2.03% | -2.82% | 38.94% | -39.89% | 7.33% | -59.97% | 30.17% | 21.15% | 152.27% |
| Book Value per Share | 2.68 | 2.30 | 1.85 | 1.98 | 1.11 | 1.13 | 0.43 | 0.54 | 0.64 | 0.74 |
| Total Shareholders' Equity | 360.15M | 352.85M | 342.91M | 476.43M | 286.38M | 307.37M | 123.05M | 160.17M | 194.04M | 230.42M |
| Common Stock | 1.48M | 1.72M | 1.94M | 2.6M | 2.65M | 2.81M | 2.81M | 2.92M | 2.94M | 3.02M |
| Retained Earnings | -779.61M | -1.06B | -1.41B | -1.77B | -2.05B | -2.3B | -2.53B | -2.68B | -2.74B | -2.77B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -71K |
| Accumulated OCI | 2.05M | -2.1M | 68K | 2.83M | 8.23M | 4.98M | -12.11M | 5.24M | 5.09M | 22.83M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
FOLD Cash Flow Statement
Amicus Therapeutics, Inc. (FOLD) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -150.53M | -215.49M | -299.95M | -250.42M | -233.29M | -202.49M | -166.57M | -69.09M | -33.89M | -33.89M |
| Operating CF Margin % | -3036.18% | -583.5% | -328.74% | -137.41% | -89.42% | -66.28% | -50.59% | -17.3% | -6.42% | - |
| Operating CF Growth % | -50.32% | -43.15% | -39.2% | 16.52% | 6.84% | 13.2% | 17.74% | 58.52% | 50.95% | -48.78% |
| Net Income | -200.04M | -284M | -349M | -356.39M | -276.85M | -250.46M | -236.57M | -151.58M | -56.11M | -14.06M |
| Depreciation & Amortization | 3.24M | 3.59M | 4.22M | 4.78M | 8.85M | 6.21M | 5.34M | 7.87M | 8.55M | 7.6M |
| Stock-Based Compensation | 17.5M | 23.1M | 29.26M | 44.43M | 49.15M | 57.84M | 76.51M | 86.08M | 84.91M | 80.04M |
| Deferred Taxes | -3.74M | -167.31M | 6.01M | -1.42M | -155K | 34K | 9K | -4.94M | 0 | 0 |
| Other Non-Cash Items | 31.37M | 234.91M | 14.28M | 46.57M | 17.78M | 2.47M | 28.01M | 41.47M | 27.71M | 16.06M |
| Working Capital Changes | 1.14M | -25.79M | -4.73M | 11.61M | -32.06M | -18.59M | -39.88M | -47.99M | -98.94M | -76.67M |
| Change in Receivables | -1.42M | -7.72M | -13.29M | -11.11M | -11.22M | -8.19M | -17.33M | -20.11M | -19.48M | -15.64M |
| Change in Inventory | -3.65M | -897K | -4.21M | -5.11M | -4.64M | -7.79M | -5.34M | -44.61M | -73.65M | -79.21M |
| Change in Payables | 7.13M | 12.56M | 17.11M | 46.74M | -10.61M | 7.43M | -6.38M | 49.2M | -16.52M | 39.6M |
| Cash from Investing | -4.51M | -171.24M | -121.2M | 95.15M | -13.58M | 78.76M | 92.32M | 98.06M | -560K | -60.33M |
| Capital Expenditures | -5.95M | -4.53M | -6.31M | -20.01M | -3.23M | -3.88M | -3.77M | -7.44M | -3.55M | -3.29M |
| CapEx % of Revenue | 120.03% | 12.26% | 6.91% | 10.98% | 1.24% | 1.27% | 1.14% | 1.86% | 0.67% | - |
| Acquisitions | 0 | 0 | 6.31M | 0 | 0 | 0 | 3.41M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 1.44M | -166.72M | -6.31M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 272.71M | 247.43M | 450.77M | 217.5M | 262.86M | 212.07M | -7.46M | 61.68M | 5.12M | -12.32M |
| Debt Issued (Net) | 192.34M | -308K | 146.26M | -420K | 230.6M | -479K | -283K | -20.96M | -97K | -83K |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 0 | 1000K | -1000K | 1000K | 1000K | 897K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -1.28M | -1.6M | -2.83M | 0 | 0 | 0 | -11.49M | 0 | 0 | 0 |
| Other Financing | -16.7M | 4.71M | 9.93M | 28.93M | 32.25M | 12.8M | 0 | -20.57M | -22.02M | -13.14M |
| Net Change in Cash | 117.54M▲ 0% | -137.97M▼ 217.4% | 31.14M▲ 122.6% | 63.97M▲ 105.4% | 19.82M▼ 69.0% | 83.29M▲ 320.3% | -96.34M▼ 215.7% | 96.96M▲ 200.6% | -33.36M▼ 134.4% | -42.95M▲ 0% |
| Free Cash Flow | -156.49M▲ 0% | -220.01M▼ 40.6% | -306.26M▼ 39.2% | -270.43M▲ 11.7% | -236.52M▲ 12.5% | -206.38M▲ 12.7% | -170.34M▲ 17.5% | -76.53M▲ 55.1% | -37.44M▲ 51.1% | 9.69M▲ 0% |
| FCF Margin % | -3156.21% | -595.75% | -335.65% | -148.39% | -90.66% | -67.55% | -51.74% | -19.16% | -7.09% | 1.62% |
| FCF Growth % | -49.1% | -40.6% | -39.2% | 11.7% | 12.54% | 12.74% | 17.46% | 55.07% | 51.07% | 130.75% |
| FCF per Share | -1.16 | -1.43 | -1.65 | -1.12 | -0.91 | -0.76 | -0.59 | -0.26 | -0.12 | -0.12 |
| FCF Conversion (FCF/Net Income) | 0.75x | 0.76x | 0.86x | 0.70x | 0.84x | 0.81x | 0.70x | 0.46x | 0.60x | -0.69x |
| Interest Paid | 0 | 0 | 7.5M | 16.97M | 24.68M | 30.47M | 34.36M | 36.09M | 58.96M | 33.17M |
| Taxes Paid | 0 | 0 | 1.06M | 691K | 10.37M | 20.03M | 1.07M | 8.53M | 8.21M | -2M |
FOLD Key Ratios
Amicus Therapeutics, Inc. (FOLD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -56.51% | -79.66% | -100.32% | -86.99% | -72.59% | -84.37% | -109.93% | -107.04% | -31.68% | -6.1% |
| Return on Invested Capital (ROIC) | -42.13% | -83.3% | -46.83% | -40.4% | -33.42% | -29.02% | -34.26% | -14.76% | 4.77% | 4.77% |
| Gross Margin | 83.2% | 83.11% | 84.21% | 87.95% | 88.1% | 88.72% | 88.28% | 90.65% | 89.98% | 89.46% |
| Net Margin | -4034.73% | -769.03% | -382.48% | -195.56% | -106.12% | -81.98% | -71.85% | -37.96% | -10.62% | -2.35% |
| Debt / Equity | 0.43x | 0.47x | 0.94x | 0.44x | 1.54x | 1.43x | 3.67x | 2.78x | 2.29x | 2.29x |
| Interest Coverage | -33.70x | -25.64x | -14.68x | -16.11x | -11.01x | -6.36x | -5.71x | -1.54x | 0.50x | 1.11x |
| FCF Conversion | 0.75x | 0.76x | 0.86x | 0.70x | 0.84x | 0.81x | 0.70x | 0.46x | 0.60x | -0.69x |
| Revenue Growth | - | 644.86% | 147.08% | 99.72% | 43.16% | 17.11% | 7.76% | 21.3% | 32.29% | 21.28% |
FOLD SEC Filings & Documents
Amicus Therapeutics, Inc. (FOLD) SEC filings — annual & quarterly reports (10-K, 10-Q)
FOLD Frequently Asked Questions
Amicus Therapeutics, Inc. (FOLD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Amicus Therapeutics, Inc. (FOLD) reported $598.7M in revenue for fiscal year 2024.
Amicus Therapeutics, Inc. (FOLD) grew revenue by 32.3% over the past year. This is strong growth.
Amicus Therapeutics, Inc. (FOLD) reported a net loss of $14.1M for fiscal year 2024.
Dividend & Returns
Amicus Therapeutics, Inc. (FOLD) has a return on equity (ROE) of -31.7%. Negative ROE indicates the company is unprofitable.
Amicus Therapeutics, Inc. (FOLD) generated $9.7M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More FOLD
Amicus Therapeutics, Inc. (FOLD) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates